|02/08/17||OraSure Announces 2016 Fourth Quarter and Full-Year Financial Results|
|BETHLEHEM, Pa., Feb. 08, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point-of-care diagnostic tests and specimen collection devices, today announced its consolidated financial results for the fourth quarter and full year ended December 31, 2016.
Financial HighlightsConsolidated net revenues for the fourth quarter of 2016 were $35.5 million, a 10% increase from the fourth quarter of 2015. Consolidated net revenues for the year ended December 31, 2016 rose to ... |
|02/06/17||OraSure Technologies Announces Settlement of Litigation with Ancestry.comDNA|
|BETHLEHEM, Pa., Feb. 06, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) today announced the settlement of litigation for patent infringement and breach of contract filed by its subsidiary, DNA Genotek, Inc. (“DNA Genotek”), against Ancestry.comDNA LLC (“Ancestry”) and Spectrum Solutions LLC (“Spectrum”), Ancestry’s contract manufacturer.
Under a Settlement and License Agreement executed by the parties, Ancestry has agreed to pay DNA Genotek a settlement fee of $12.5 mill... |
|01/11/17||OraSure Technologies Earnings Conference Call Invitation|
|2016 Fourth Quarter Earnings Conference Call Wednesday, February 8, 2017, 5:00 p.m. ET
BETHLEHEM, Pa., Jan. 11, 2017 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR) has scheduled its regular earnings conference call covering 2016 fourth quarter financial results, 2017 first quarter financial guidance and certain business developments for 5:00 pm ET (2:00 pm PT) on Wednesday, February 8, 2017.
February 8, 2017 Schedule
|11/29/16||OraSure to Implement $18 Million Product Supply Contract From Foreign Government for HCV Elimination Program|
|BETHLEHEM, Pa., Nov. 29, 2016 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, announced today that it will begin fulfilling a contract to supply a foreign government with $18 million of product, primarily to support a nationwide hepatitis C (HCV) testing and treatment program with the goal of eliminating HCV infection across the country by 2020.
The contract calls for the purchase of $16 million of Ora... |